Major drugmakers were trading sharply lower on Tuesday as Wall Street is bracing for a broader set of tariffs that President ...

Merck & Co has announced the first presentation of full results from the Phase III ZENITH trial of Winrevair ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET ...

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and ...

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...

Merck (MRK) announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR compared to placebo in adults with ...

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $111.88, a 25.38% upside from current levels. In a report released on March 28, Leerink Partners also ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...